CVS split talks leave Caremark as the unanswered question

CVS is considering separating retail pharmacy from insurance, according to reported discussions, with no decision described. The financial question is which relationships among Aetna, Caremark and the pharmacy network would survive separate ownership, and at what cost.

CVS is considering a separation of its retail pharmacy and insurance operations, according to Reuters reporting. The report describes exploratory discussions rather than a completed decision. The unresolved issue is where Caremark, the pharmacy benefit manager connecting drug manufacturers, plans and patients, would sit in any new structure.

What the discussions leave unresolved

CVS combines about 9,000 pharmacies with Aetna insurance and Caremark pharmacy benefit management. It acquired Aetna for $78 billion in 2018 and has explored a breakup before. The account provided here does not specify Caremark's place in a potential separation or explain how the current exploration differs from the earlier one.

That distinction matters because separating retail pharmacy from insurance leaves several possible boundaries between the businesses. The ownership of Caremark would help determine which purchasing arrangements, member referrals, clinical programmes, data relationships and pharmacy access agreements might need to operate through contracts.

Revenue measures scale, not breakup value

The company's results center shows second quarter 2026 revenue of $106.1 billion and projected full year revenue of at least $414.0 billion. These are figures for different reporting periods and should not be interpreted as a growth comparison.

Consolidated revenue establishes the size of the business under review. The financial case for separation would instead depend on the operating profit, cash generation, financing requirements and debt assigned to each resulting company. Those allocations are absent from the figures presented here.

Caremark determines where coordination changes

Retail pharmacy faces reimbursement pressure, staffing costs and prescription volumes. Insurance earns premium revenue and carries claims risk. Caremark operates between drug manufacturers, plans and patients, making its position consequential for both businesses.

If Caremark remained with Aetna, a separate retail company could have to negotiate arrangements previously handled within the group. If Caremark remained with retail pharmacy, Aetna could face that contractual boundary instead. These are possible structures, not reported proposals.

Commercial agreements could preserve purchasing, referrals, data sharing, clinical programmes and pharmacy access after separation. The relevant economic test is whether those agreements preserve enough of the benefits of common ownership to offset additional contracting and duplicated operating costs.

Separation needs a financial case

A split could give retail pharmacy and insurance clearer standalone valuations and more focused management. That is a possible advantage, rather than evidence of a valuation uplift.

The suggestion that insurance could allocate capital without funding the store network assumes an existing funding relationship that the available figures do not establish. Any credible comparison would need to account for intercompany funding, allocated debt, regulatory capital requirements and the costs of replacing shared operations.

A formal separation plan would also need tax, debt and regulatory structures. Until the proposed perimeter and financial allocations are known, neither the benefit of separate valuations nor the cost of lost coordination can be measured.

Scenarios over three years

Over the next three months, the next CVS filing and management commentary may clarify whether discussions have advanced and which businesses are being considered for separation. Revised segment reporting alone would not establish a board decision; a formal announcement would provide a clearer change in status.

Over 12 months, if a plan emerges, its treatment of Caremark, debt, shared services and regulatory obligations will be more informative than consolidated revenue. Subsequent standalone margins, after duplicated costs and retained coordination, would provide a stronger test of the financial outcome.

What settles it

The account provides no date for a separation decision. The decisive next signal is a formal CVS plan identifying which businesses would separate and how Caremark would be treated.